Cargando…

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry

BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus...

Descripción completa

Detalles Bibliográficos
Autores principales: Boegemann, Martin, Goebell, Peter Jürgen, Woike, Michael, Buncke, Johanna, Schlack, Katrin, Schrader, Andres Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/
https://www.ncbi.nlm.nih.gov/pubmed/34804848
http://dx.doi.org/10.21037/tau-20-938
_version_ 1784595697547345920
author Boegemann, Martin
Goebell, Peter Jürgen
Woike, Michael
Buncke, Johanna
Schlack, Katrin
Schrader, Andres Jan
author_facet Boegemann, Martin
Goebell, Peter Jürgen
Woike, Michael
Buncke, Johanna
Schlack, Katrin
Schrader, Andres Jan
author_sort Boegemann, Martin
collection PubMed
description BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus treated cohort and compared the results with the physician’s prognosis. METHODS: A German multicenter registry (STAR-TOR) for a/mRCC patients (NCT00700258) was established to evaluate the efficacy and safety of temsirolimus 25 mg weekly in a routine clinical setting. These prospective data were systematically analyzed and followed-up by an independent clinical research organization to compare established prognostic scores (MSKCC, IMDC and Hudes) with the risk assessment by treating physicians based on their medical expertise and match them with survival outcomes. RESULTS: This interim analysis included 547 patients between 02/2008 and 05/2015 in 87 centers. Either prognostic tool resulted in significant and clinically meaningful differentiation between good, intermediate and poor prognosis. However, physician’s prognosis identified more patients with good prognosis (9.1% vs. 1.3%). In patients with good physician’s prognosis and intermediate prognosis by MSKCC, overall survival was nearly doubled compared to consensual intermediate prognosis (26.6 vs. 13.6 months), albeit without reaching statistical significance (P=0.09). For poor prognosis assessed by the physician, MSKCC performed statistically better for differentiation between poor and intermediate prognosis with a median overall survival of 10.3 vs. 5.5 months (P<0.01). CONCLUSIONS: Physician’s prognosis may be able to identify a subset of patients treated with temsirolimus with good prognosis when MSKCC-determines intermediate prognosis while the MSKCC score could identify patients which were falsely placed in the poor risk group by physicians.
format Online
Article
Text
id pubmed-8575558
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85755582021-11-18 Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry Boegemann, Martin Goebell, Peter Jürgen Woike, Michael Buncke, Johanna Schlack, Katrin Schrader, Andres Jan Transl Androl Urol Original Article on Management of Advanced Genitourinary Malignancies BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the prognostic value of these scores in a large temsirolimus treated cohort and compared the results with the physician’s prognosis. METHODS: A German multicenter registry (STAR-TOR) for a/mRCC patients (NCT00700258) was established to evaluate the efficacy and safety of temsirolimus 25 mg weekly in a routine clinical setting. These prospective data were systematically analyzed and followed-up by an independent clinical research organization to compare established prognostic scores (MSKCC, IMDC and Hudes) with the risk assessment by treating physicians based on their medical expertise and match them with survival outcomes. RESULTS: This interim analysis included 547 patients between 02/2008 and 05/2015 in 87 centers. Either prognostic tool resulted in significant and clinically meaningful differentiation between good, intermediate and poor prognosis. However, physician’s prognosis identified more patients with good prognosis (9.1% vs. 1.3%). In patients with good physician’s prognosis and intermediate prognosis by MSKCC, overall survival was nearly doubled compared to consensual intermediate prognosis (26.6 vs. 13.6 months), albeit without reaching statistical significance (P=0.09). For poor prognosis assessed by the physician, MSKCC performed statistically better for differentiation between poor and intermediate prognosis with a median overall survival of 10.3 vs. 5.5 months (P<0.01). CONCLUSIONS: Physician’s prognosis may be able to identify a subset of patients treated with temsirolimus with good prognosis when MSKCC-determines intermediate prognosis while the MSKCC score could identify patients which were falsely placed in the poor risk group by physicians. AME Publishing Company 2021-10 /pmc/articles/PMC8575558/ /pubmed/34804848 http://dx.doi.org/10.21037/tau-20-938 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article on Management of Advanced Genitourinary Malignancies
Boegemann, Martin
Goebell, Peter Jürgen
Woike, Michael
Buncke, Johanna
Schlack, Katrin
Schrader, Andres Jan
Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title_full Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title_fullStr Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title_full_unstemmed Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title_short Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
title_sort assessment of prognosis by established prognosis scores and physicians’ judgement in mrcc patients: an analysis of the star-tor registry
topic Original Article on Management of Advanced Genitourinary Malignancies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575558/
https://www.ncbi.nlm.nih.gov/pubmed/34804848
http://dx.doi.org/10.21037/tau-20-938
work_keys_str_mv AT boegemannmartin assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry
AT goebellpeterjurgen assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry
AT woikemichael assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry
AT bunckejohanna assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry
AT schlackkatrin assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry
AT schraderandresjan assessmentofprognosisbyestablishedprognosisscoresandphysiciansjudgementinmrccpatientsananalysisofthestartorregistry